Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imitrodast SCHEMBL99497 | 0.99 | TBXAS1 (0.98) | TBXAS1 | |
| Imitrodast SCHEMBL8156405 | 0.89 | TBXAS1 (0.81) | TBXAS1 | |
| SCHEMBL9835155 | 0.88 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL9836779 | 0.86 | TBXAS1 (0.76) | TBXAS1 | |
| SCHEMBL9836523 | 0.85 | TBXAS1 (0.74) | TBXAS1 | |
| Imitrodast SCHEMBL1794449 | 0.84 | TBXAS1 (0.71) | TBXAS1 | |
| SCHEMBL9834831 | 0.81 | TBXAS1 (0.69) | TBXAS1 | |
| SCHEMBL9836890 | 0.81 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL9401596 | 0.80 | TBXAS1 (0.67) | TBXAS1 | |
| SCHEMBL9401600 | 0.80 | TBXAS1 (0.67) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962797-B2 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2024-05-29 | — | — | EP | claimed |
| EP-1962797-B1 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2020-10-28 | — | — | EP | claimed |
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | claimed |
| EP-3354263-A1 | DRY POWDER FORMULATIONS | Jagotec AG (CH) | 2018-08-01 | — | — | EP | claimed |
| EP-3275435-A1 | DRY POWDER FORMULATIONS | Jagotec AG (CH) | 2018-01-31 | — | — | EP | claimed |
| EP-1689360-B1 | DRY POWDER FORMULATIONS | JAGOTEC AG (CH) | 2017-08-23 | — | — | EP | claimed |
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150037425-A1 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2015-02-05 | — | — | US | claimed |
| CN-104224720-A | DRY POWDER FORMULATIONS | JAGOTEC AG | 2014-12-24 | — | — | CN | claimed |
| US-20070071690-A1 | Dry powder formulations | JAGOTEC AG (CH) | 2007-03-29 | — | — | US | claimed |
| CN-1878537-A | Dry powder formulations | JAGOTEC AG (CH) | 2006-12-13 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1131059-B1 | DRY POWDER FOR INHALATION | JAGO RES AG (CH) | 2003-03-05 | — | — | EP | claimed |
| EP-1283036-A1 | Dry powder for inhalation | JAGO RESEARCH AG (CH) | 2003-02-12 | — | — | EP | claimed |
| EP-1131059-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2001-09-12 | — | — | EP | claimed |
| WO-2000028979-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2000-05-25 | — | — | WO | claimed |
| EP-0240107-B1 | THIANAPHTHENE DERIVATIVES, THEIR PRODUCTION AND USE | Sankyo Company Limited (JP) | 1991-08-21 | — | — | EP | claimed |
| US-4847272-A | ANTICOAGULANTS | SANKYO COMPANY LIMITED (JP) | 1989-07-11 | — | — | US | claimed |
| EP-0240107-A1 | Thianaphthene derivatives, their production and use | Sankyo Company Limited (JP) | 1987-10-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | SAE1, SDC4, SPECC1L | TBXAS1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.